A small biotechnology company with a promising new treatment in Phase II commissioned Aquest to quantitatively evaluate potential US and EU demand for the product as well as assess the impact on demand of various patient and product attributes. Aquest designed several specific patient profiles that could be presented randomly to physicians in order to obtain more accurate usage expectations. Share reactions to various attribute alternatives also shed light on the relationship between key product attributes and demand. The final report allowed comparisons between U.S. perceptions/usage and those of the various EU countries involved. The company used the results to support further funding for their product.